Since AAV gene therapy’s origins, scientists and regulators have sought optimized ways to measure empty/full capsids. This expert reviews pros and cons of modern methods.
- AI-Assisted QMS: Bridging ISO/IEC 42001:2023 And ICH Q10 For Pharmaceutical Excellence
- Navigating FDA Regulatory Changes: Policy Shifts, Deregulation, Restructuring, And Future Oversight
- Rethinking Academic Translation In CGT: Inside The RISE Framework At Mass General Brigham
- How Is RIM Software Transforming Regulatory Compliance?
- EMA Guideline On Clinical-Stage ATMPs Comes Into Effect: On The Verge Of Convergence?
- Exploring The Market For Closed-Loop Cell Therapy Production
- Closed-Loop Manufacturing Is The Cell Therapy Revolution We Need
- What Global Survey Says About Scant Patient Access To CAR-T Therapy
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Business Continuity Management: The Benzonase® Endonuclease Success Story
Business continuity management is a key success contributor to the pharma industry. Explore best practices for a robust supply chain and how they can translate into success stories.
-
Peptide Mapping Study On Human Erythropoietin
A newly integrated and easy-to-use peptide mapping workflow for the analysis of standard monoclonal antibodies provides a streamlined workflow for the analysis of both CID and EAD data.
-
The Key To Viral Vector Success
Establishing a robust and scalable viral vector process requires a multidisciplinary approach that incorporates expertise in foundational science, analytics, and biomanufacturing.
-
Rapid, Seamless Upstream Process Development And Scale-Up For CHO-K1 Cells
Accelerate your biotech company's scale-up process while delivering consistent and strong cell growth, productivity, and product quality.
-
Fast And Scalable Fc Quantitation In Supernatants
In biopharmaceutical development, the Fc PAIA Titer assay offers a fast, cost-effective, and automatable solution for high-throughput Fc quantification to enhance efficiency, support research, and accelerate production advancements.
-
Uninterrupted Supply To Meet Demand
Explore a solution for biopharmaceutical companies concerned about the risks an increase in campaign volume can pose to their production timeline.
-
Cell-Free Modeling Approach For Efficient Cell Culture Monitoring
Learn about a novel cell-free modeling method for the efficient monitoring of cell cultures that has significant advantages over traditional approaches.
-
Expansion Of Specific Lymphocytes With A Xeno-Free, Serum-Free Medium
Explore the advantages of utilizing a xeno- and serum-free medium for the targeted expansion of cell subpopulations without the addition of serum.
-
Study Viral Infection In Resting Human CD4+ T Cells
Explore a study proving how synthetic single guide RNAs were used to optimize the editing conditions for resting human CD4+ T cells and maintain high cell viability for several weeks post Nucleofection.
-
Intuitive Bioprocess Scale-Up From Bench Scale To Pilot Scale
This study explores scaling a high-demand fed-batch process from bench to pilot scale, highlighting control parameter differences at 50L and 500L while maintaining consistent growth and product titers.
NEWSLETTER ARCHIVE
- 06.24.25 -- STREAM Edition: Major Advancements In mRNA
- 06.24.25 -- Overcoming Manufacturing Hurdles To Scale iPSC Therapies
- 06.23.25 -- Rethinking CGT Biotech Growth & Investment With Audrey Greenberg
- 06.20.25 -- Navigating CGT Biotech's Financial Headwinds And The Path Forward
- 06.19.25 -- Cleaning Process Capability: Understanding Populations, Samples, And Sample Size Requirements

- Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More
- Rethinking Academic Translation In CGT: Inside The RISE Framework At Mass General Brigham
- The Promise Of Focused Ultrasound For AAV Gene Therapy Delivery
- Unlocking The Potential Of iPSC Therapies In Regenerative Medicine
- Ferring Builds A Global Gene Therapy Manufacturing Network Around ADSTILADRIN
CELL AND GENE CONTENT COLLECTIONS

While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections